Novavax, Inc. (NVAX)
NASDAQ: NVAX · IEX Real-Time Price · USD
15.50
+0.35 (2.31%)
At close: May 24, 2024, 4:00 PM
15.57
+0.07 (0.45%)
After-hours: May 24, 2024, 7:59 PM EDT

Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of $2.18 billion. The enterprise value is $1.91 billion.

Market Cap 2.18B
Enterprise Value 1.91B

Important Dates

The last earnings date was Friday, May 10, 2024, before market open.

Earnings Date May 10, 2024
Ex-Dividend Date n/a

Share Statistics

Novavax has 140.40 million shares outstanding. The number of shares has increased by 62.39% in one year.

Shares Outstanding 140.40M
Shares Change (YoY) +62.39%
Shares Change (QoQ) +38.85%
Owned by Insiders (%) 4.97%
Owned by Institutions (%) 57.45%
Float 124.18M

Valuation Ratios

PE Ratio n/a
Forward PE 1.78
PS Ratio 2.18
Forward PS 2.79
PB Ratio n/a
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1.92
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.90

Current Ratio 0.90
Quick Ratio 0.64
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -26.84

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -24.60%
Return on Capital (ROIC) n/a
Revenue Per Employee $645,890
Profits Per Employee -$258,397
Employee Count 1,543
Asset Turnover 0.61
Inventory Turnover 14.77

Taxes

In the past 12 months, Novavax has paid $3.11 million in taxes.

Income Tax 3.11M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +112.62% in the last 52 weeks. The beta is 1.62, so Novavax's price volatility has been higher than the market average.

Beta (1Y) 1.62
52-Week Price Change +112.62%
50-Day Moving Average 6.53
200-Day Moving Average 6.14
Relative Strength Index (RSI) 79.01
Average Volume (30 Days) 12,952,250

Short Selling Information

The latest short interest is 44.93 million, so 32.00% of the outstanding shares have been sold short.

Short Interest 44.93M
Short Previous Month 43.77M
Short % of Shares Out 32.00%
Short % of Float 36.19%
Short Ratio (days to cover) 12.31

Income Statement

In the last 12 months, Novavax had revenue of $996.61 million and -$398.71 million in losses. Loss per share was -$3.13.

Revenue 996.61M
Gross Profit 627.72M
Operating Income -398.57M
Pretax Income -395.60M
Net Income -398.71M
EBITDA -337.06M
EBIT -381.39M
Loss Per Share -$3.13
Full Income Statement

Balance Sheet

The company has $491.04 million in cash and $229.33 million in debt, giving a net cash position of $261.71 million or $1.86 per share.

Cash & Cash Equivalents 491.04M
Total Debt 229.33M
Net Cash 261.71M
Net Cash Per Share $1.86
Equity / Book Value -867.08M
Book Value Per Share -6.18
Working Capital -77.26M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$471.93 million and capital expenditures -$42.50 million, giving a free cash flow of -$514.43 million.

Operating Cash Flow -471.93M
Capital Expenditures -42.50M
Free Cash Flow -514.43M
FCF Per Share -$3.68
Full Cash Flow Statement

Margins

Gross margin is 62.99%, with operating and profit margins of -39.99% and -40.01%.

Gross Margin 62.99%
Operating Margin -39.99%
Pretax Margin -39.69%
Profit Margin -40.01%
EBITDA Margin -33.82%
EBIT Margin -38.27%
FCF Margin -51.62%

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -62.39%
Shareholder Yield -62.39%
Earnings Yield -18.32%
FCF Yield -23.64%

Analyst Forecast

The average price target for Novavax is $17.50, which is 12.90% higher than the current price. The consensus rating is "Buy".

Price Target $17.50
Price Target Difference 12.90%
Analyst Consensus Buy
Analyst Count 4
Revenue Growth Forecast (5Y) 2.65%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on May 10, 2019. It was a reverse split with a ratio of 1:20.

Last Split Date May 10, 2019
Split Type Reverse
Split Ratio 1:20

Scores

Novavax has an Altman Z-Score of -4.81 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -4.81
Piotroski F-Score 2